Adenine

Biochem/physiol Actions MRS 1191 is putative A3 adenosine receptor antagonist, highly selective for human A3 receptor vs human A1 receptor. MRS 1067, MRS 1191 and MRS 1220 were found to be competitive in saturation binding studies using the

Biochem/physiol Actions MRS 1191 is putative A3 adenosine receptor antagonist, highly selective for human A3 receptor vs human A1 receptor. MRS 1067, MRS 1191 and MRS 1220 were found to be competitive in saturation binding studies using the

Biochem/physiol Actions MRS1220 is a putative A3 adenosine receptor antagonist. MRS 1220 was found to be competitive in saturation binding studies using the agonist radioligand 125 I AB-MECA at cloned human brain A3 receptors expressed in

A selective adenosine A3 receptor antagonist (Kis = 18.9 and 113 nM for human and rat A3 receptors, respectively, versus Kis = 15.6 and 2.05 &microM for rat A1 and A2A receptors, respectively).

N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor , with Ki of 29 nM for Rat ecto-5′-Nucleotidase.IC50 value: 29.0 ± 1.7 nM (Ki)Target: Adenosine ReceptorForm:Solid.

N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor , with Ki of 29 nM for Rat ecto-5′-Nucleotidase.IC50 value: 29.0 ± 1.7 nM (Ki)Target: Adenosine ReceptorForm:Solid.

N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor , with Ki of 29 nM for Rat ecto-5′-Nucleotidase.IC50 value: 29.0 ± 1.7 nM (Ki)Target: Adenosine ReceptorForm:Solid.

Biochem/physiol Actions NCT-503 is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first, rate-limiting step of glucose-derived serine synthesis. NCT-503 reduced glucose-derived serine production and suppressed the

Biochem/physiol Actions NCT-503 is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first, rate-limiting step of glucose-derived serine synthesis. NCT-503 reduced glucose-derived serine production and suppressed the

A PHGDH inhibitor that blocks serine synthesis from 3-phosphoglycerate in cells (IC₅₀ = 2.5 &microM) reduces the production of glucose-derived serine in cells and suppresses the growth of PHGDH-dependent MDA-MB-468 cancer cells both in

A PHGDH inhibitor that blocks serine synthesis from 3-phosphoglycerate in cells (IC₅₀ = 2.5 &microM) reduces the production of glucose-derived serine in cells and suppresses the growth of PHGDH-dependent MDA-MB-468 cancer cells both in

A PHGDH inhibitor that blocks serine synthesis from 3-phosphoglycerate in cells (IC₅₀ = 2.5 &microM) reduces the production of glucose-derived serine in cells and suppresses the growth of PHGDH-dependent MDA-MB-468 cancer cells both in